Tegean Capital Management’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Tegean Capital Management’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-22,855	Closed	-$407	–	27
2022 Q4	$407	Hold	22,855	–	–	﹤0.01%	11
2022 Q3	$2K	Hold	22,855	–	–	﹤0.01%	23
2022 Q2	$2K	Hold	22,855	–	–	﹤0.01%	50
2022 Q1	$5K	Hold	22,855	–	–	0.01%	54
2021 Q4	$12K	Buy	+22,855	New	+$13K	0.01%	57

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Tegean Capital Management's IBER.WS Position: Q1 2023 in Review

Tegean Capital Management sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 22,855 shares — an estimated $407 sold.

Tegean Capital Management first reported a position in IBER.WS in Q4 2021 and held it in 5 quarters. The position peaked at $12K in Q4 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Tegean Capital Management reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Tegean Capital Management sold 22,855 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $407.
Tegean Capital Management first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q4 2021 and held it in 5 quarters.
Tegean Capital Management's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $12K in Q4 2021.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Tegean Capital Management's 13F filing for Q1 2023, filed 15 May 2023.